Magnesium Sulfate

Identification

Name
Magnesium Sulfate
Accession Number
DB00653  (APRD01080)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Structure
Thumb
Synonyms
  • Magnesium sulfate (1:1)
  • Magnesium sulfate anhydrous
  • Magnesium sulphate
  • Magnesium(ii) sulfate
  • Magnesiumsulfat
  • MgSO4
Product Ingredients
IngredientUNIICASInChI Key
Magnesium sulfate heptahydrateSK47B8698T10034-99-8WRUGWIBCXHJTDG-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
50% Magnesium Sulfate Injection USPSolution500 mgIntramuscular; IntravenousHospira, Inc.1975-12-31Not applicableCanada
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2015-09-16Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousFresenius Kabi2016-01-29Not applicableUs
Magnesium SulfateInjection, solution4 g/50mLIntravenousHospira, Inc.1994-06-24Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2017-01-13Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousCardinal Health2000-08-08Not applicableUs
Magnesium SulfateInjection, solution4 g/100mLIntravenousHospira, Inc.1994-06-24Not applicableUs
Magnesium SulfateInjection, solution4 g/100mLIntravenousA S Medication Solutions1994-06-242017-06-20Us
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousFresenius Kabi2000-08-08Not applicableUs
Magnesium Sulfate DressingLiquid45 %TopicalDumex Medical Canada Inc.Not applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousX Gen Pharmaceuticals, Inc.2014-02-23Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Magnesium SulfateInjection1 g/100mLIntravenousWG Critical Care, LLC2016-03-08Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousHospira, Inc.1987-07-22Not applicableUs
Magnesium SulfateInjection, solution80 mg/mLIntravenousFresenius Kabi Norge As2017-08-01Not applicableUs
Magnesium SulfateInjection, solution80 mg/mLIntravenousFresenius Kabi2016-03-15Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousHospira, Inc.2000-04-25Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2006-12-12Not applicableUs
Magnesium SulfateInjection, solution40 mg/mLIntravenousFresenius Kabi Norge As2017-08-02Not applicableUs
Magnesium SulfateInjection, solution40 mg/mLIntravenousFresenius Kabi2016-03-15Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Assured Epsom SaltGranule100 g/100gOralGreenbrier International, Inc.2016-06-14Not applicableUs
Assured Epsom SaltGranule100 g/100gOralHefei Yatai Daily Chemical Products Co., Ltd.2016-03-30Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalSupervalu2005-03-21Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalPublix Supermarkets, Inc.2014-09-05Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalWalgreens2015-07-13Not applicableUs
Epsom SaltGranule, for solution1 g/gOralCVS Health1998-07-15Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalValue Merchandisers2014-10-15Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalWinco Foods2015-05-21Not applicableUs
Epsom SaltGranule1 g/gOral; TopicalSunmark (Mckesson)2014-08-18Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalWakfern Food Corporation2014-05-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Epsom SaltGranule, for solution1 g/gOral; TopicalJubilant, Llc2017-10-01Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousAmerican Regent1990-09-302017-07-20Us
Magnesium SulfateInjection, solution.5 g/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-08-012017-01-28Us
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousAmerican Regent1990-09-302017-07-20Us
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-09-012017-04-01Us
Magnesium SulfateInjection, solution20 g/250mLIntravenousCantrell Drug Company2011-07-25Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousAmerican Regent1990-09-302017-07-20Us
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousCardinal Health2000-08-082017-07-19Us
Magnesium SulfateInjection, solution20 g/500mLIntravenousCantrell Drug Company2011-02-21Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium Lactate Et Magnesium SulfateMagnesium Sulfate (65 mg) + Calcium lactate (260 mg)TabletOralBio Vita1987-12-312005-07-20Canada
ColPrep KitMagnesium Sulfate (1.6 g/22.7g) + Potassium sulfate (3.13 g/22.7g) + Sodium sulfate (17.5 g/22.7g)Powder, for solutionOralKvk Tech,Inc2016-12-27Not applicableUs
Concept DHAMagnesium Sulfate (5 mg/1) + Biotin (300 ug/1) + Cupric sulfate (2 mg/1) + Cyanocobalamin (12.5 ug/1) + Folic Acid (1 mg/1) + Iron (53.5 mg/1) + Iron (38 mg/1) + Niacin (1.8 mg/1) + Omega-3-acid ethyl esters (200 mg/1) + Calcium pantothenate (5 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3 mg/1) + Thiamine mononitrate (2 mg/1) + Vitamin C (25 mg/1) + Zinc sulfate (10 mg/1)Capsule, liquid filledOralUs Pharmaceutical Corporation2009-06-24Not applicableUs
Concept OBMagnesium Sulfate (6.9 mg/1) + Biotin (300 ug/1) + Cupric sulfate (800 ug/1) + Cyanocobalamin (10 ug/1) + Folic Acid (1 mg/1) + Iron (130 mg/1) + Iron (92.4 mg/1) + Manganese sulfate (1.3 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (7 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (5 mg/1) + Thiamine mononitrate (5 mg/1) + Vitamin C (210 mg/1) + Zinc sulfate (18.2 mg/1)CapsuleOralUs Pharmaceutical Corporation2009-01-01Not applicableUs
Eau Purgative RigaMagnesium Sulfate (2.4 g) + Sodium sulfate (1.056 g)LiquidOralGlendale Agencies1978-12-311996-11-29Canada
Magnesium CapMagnesium Sulfate (111 mg) + Magnesium oxide (82 mg)CapsuleOralAlsi Cie Ltee1983-12-312002-06-12Canada
Magnesium Sulfate In 5% Dextrose Inj(20mg/ml)Magnesium Sulfate (20 mg) + Glucose (50 mg)SolutionIntravenousHospira, Inc.1996-12-30Not applicableCanada
Multiple Electrolyte Additive InjMagnesium Sulfate (19.8 mg) + Calcium gluconate (20.6 mg) + Potassium Chloride (29.8 mg) + Sodium Chloride (46.6 mg)LiquidIntravenousInternational Medication Systems, Limited1980-12-311997-08-15Canada
Solution CardaMagnesium Sulfate (.003 %) + Potassium bicarbonate (.01 %) + Sodium bicarbonate (.566 %)LiquidOralLaboratoire Atlas Inc1984-12-311996-09-09Canada
SuclearMagnesium Sulfate (1.6 gm) + Polyethylene glycol (210 gm) + Potassium sulfate (3.13 gm) + Potassium Chloride (0.74 gm) + Sodium Chloride (5.6 gm) + Sodium bicarbonate (2.86 gm) + Sodium sulfate (17.5 gm)KitOralBraintree Laboratories2013-01-182016-08-31Us
Categories
UNII
ML30MJ2U7I
CAS number
7487-88-9
Weight
Average: 120.368
Monoisotopic: 119.936771076
Chemical Formula
MgO4S
InChI Key
CSNNHWWHGAXBCP-UHFFFAOYSA-L
InChI
InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
IUPAC Name
magnesium(2+) ion sulfate
SMILES
[Mg++].[O-]S([O-])(=O)=O

Pharmacology

Indication

Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.

Structured Indications
Pharmacodynamics

Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.

Mechanism of action

Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca2+ influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.

TargetActionsOrganism
UVoltage-dependent calcium channel gamma-1 subunitNot AvailableHuman
UVoltage-dependent calcium channel subunit alpha-2/delta-1Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1CNot AvailableHuman
UVoltage-dependent L-type calcium channel subunit beta-1Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit beta-2Not AvailableHuman
UVoltage-dependent L-type calcium channel subunit alpha-1SNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

25-30%

Metabolism

None

Route of elimination

Magnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.

Half life

43.2 hours (for newborns)

Clearance
Not Available
Toxicity

LD50 = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Magnesium Sulfate.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Magnesium Sulfate.Vet Approved
7-NitroindazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcepromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AdipiplonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AgomelatineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Alaproclate.Experimental
AlcuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Alcuronium.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Sulfate.Approved
AlfacalcidolThe serum concentration of Magnesium Sulfate can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlfaxaloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Investigational
AllopregnanoloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlphacetylmethadolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmisulprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium Sulfate.Approved
AmobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Magnesium Sulfate.Approved, Investigational
AmoxapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Magnesium Sulfate.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium Sulfate.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Magnesium Sulfate.Approved, Investigational
AripiprazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Magnesium Sulfate.Approved
ArticaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Atosiban.Approved, Investigational
AtracuriumMagnesium Sulfate may increase the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateMagnesium Sulfate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium Sulfate.Approved, Investigational
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium Sulfate.Investigational
BaclofenMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Magnesium Sulfate.Experimental
BarbexacloneThe metabolism of Magnesium Sulfate can be increased when combined with Barbexaclone.Experimental
BarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium Sulfate.Approved
BencyclaneThe risk or severity of adverse effects can be increased when Bencyclane is combined with Magnesium Sulfate.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium Sulfate.Approved, Investigational
BenperidolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Magnesium Sulfate.Approved
Benzyl alcoholMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Sulfate.Approved, Withdrawn
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Magnesium Sulfate.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Magnesium Sulfate.Experimental
BrexpiprazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromisovalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromperidolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Investigational
BrompheniramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Magnesium Sulfate.Investigational
BunazosinBunazosin may increase the hypotensive activities of Magnesium Sulfate.Investigational
BupivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Magnesium Sulfate.Approved
ButethalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Magnesium Sulfate.Approved
ButorphanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CalcitriolThe serum concentration of Magnesium Sulfate can be increased when it is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Magnesium Sulfate.Withdrawn
CanertinibMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Magnesium Sulfate.Experimental
CarbamazepineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarbomycinThe metabolism of Magnesium Sulfate can be decreased when combined with Carbomycin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Magnesium Sulfate.Investigational
CarfentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CaroverineThe risk or severity of adverse effects can be increased when Caroverine is combined with Magnesium Sulfate.Experimental
CarvedilolCarvedilol may increase the hypotensive activities of Magnesium Sulfate.Approved, Investigational
CaseinThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Magnesium Sulfate.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Magnesium Sulfate.Approved
CetirizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Magnesium Sulfate.Approved
ChlorphenamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineMagnesium Sulfate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorzoxazoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Magnesium Sulfate.Approved, Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium Sulfate.Approved, Investigational
CimetidineThe serum concentration of Magnesium Sulfate can be increased when it is combined with Cimetidine.Approved
CinchocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium Sulfate.Approved, Investigational
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational, Withdrawn
CisatracuriumMagnesium Sulfate may increase the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateMagnesium Sulfate may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CitalopramThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Citalopram.Approved
ClarithromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Clarithromycin.Approved
ClemastineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Sulfate.Approved
ClidiniumMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
clomethiazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopenthixolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Magnesium Sulfate.Approved, Nutraceutical
ClorazepateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClothiapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Magnesium Sulfate.Approved, Vet Approved
ClozapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Magnesium Sulfate.Investigational
CyclizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
CyproheptadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Magnesium Sulfate.Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium Sulfate.Experimental
DecamethoniumMagnesium Sulfate may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium Sulfate.Approved
DemeclocyclineMagnesium Sulfate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeramciclaneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DesfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Desvenlafaxine.Approved
DetomidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Magnesium Sulfate.Vet Approved
Diethyl etherMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
DifenoxinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium Sulfate.Approved
DimenhydrinateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium Sulfate.Approved
DixyrazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium Sulfate.Approved
Domoic AcidMagnesium Sulfate may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DoramectinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium Sulfate.Investigational
Doxacurium chlorideMagnesium Sulfate may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Magnesium Sulfate.Approved
DoxepinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxycyclineMagnesium Sulfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DoxylamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
DrotebanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Duloxetine.Approved
DyclonineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Magnesium Sulfate.Approved
EcopipamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Magnesium Sulfate.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium Sulfate.Approved, Investigational
EltanoloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium Sulfate.Approved
EnfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
EntacaponeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium Sulfate.Approved, Investigational
ErythromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Escitalopram.Approved, Investigational
EstazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Experimental, Investigational
Ethyl loflazepateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Sulfate.Approved
EtifoxineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtizolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Etoperidone.Withdrawn
EtorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Sulfate.Approved, Investigational
FencamfamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium Sulfate.Withdrawn
FentanylMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Magnesium Sulfate.Experimental
FexofenadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium Sulfate.Approved
FlibanserinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluanisoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FluconazoleThe serum concentration of Magnesium Sulfate can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Magnesium Sulfate.Approved
FludiazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Magnesium Sulfate.Withdrawn
FlunarizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Magnesium Sulfate.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fluvastatin.Approved
FluvoxamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Magnesium Sulfate.Approved
FospropofolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
GabapentinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
GallamineMagnesium Sulfate may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideMagnesium Sulfate may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Magnesium Sulfate.Investigational
Gamma Hydroxybutyric AcidMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
GepironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Magnesium Sulfate.Experimental
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium Sulfate.Investigational, Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Magnesium Sulfate.Approved, Vet Approved
GuanfacineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Magnesium Sulfate.Experimental
HalazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Magnesium Sulfate.Approved, Withdrawn
HalothaneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Magnesium Sulfate.Approved, Investigational
HexobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HydrocodoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
IloperidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Indalpine.Investigational, Withdrawn
IndiplonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
IndoraminIndoramin may increase the hypotensive activities of Magnesium Sulfate.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Magnesium Sulfate.Approved
IsofluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium Sulfate.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Magnesium Sulfate.Approved, Investigational
JosamycinThe metabolism of Magnesium Sulfate can be decreased when combined with Josamycin.Approved, Investigational
KetamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Magnesium Sulfate.Approved, Investigational
KitasamycinThe metabolism of Magnesium Sulfate can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Magnesium Sulfate.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium Sulfate.Approved, Investigational
LamotrigineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium Sulfate.Approved, Investigational
LevetiracetamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
Levomethadyl AcetateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Levomilnacipran.Approved
LevorphanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium Sulfate.Approved
LidocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Lidoflazine is combined with Magnesium Sulfate.Experimental
Lipoic AcidMagnesium Sulfate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LithiumMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LoprazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LormetazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LovastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Lovastatin.Approved, Investigational
LoxapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LurasidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium salicylate.Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium Sulfate.Approved, Investigational
MaprotilineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MebicarMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MeclizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Mefloquine.Approved
MelatoninMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Magnesium Sulfate.Experimental
MepivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MesoridazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MetaxaloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrileneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylecgonineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
MethylphenobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetocurineMagnesium Sulfate may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMagnesium Sulfate may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetyrosineMagnesium Sulfate may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Magnesium Sulfate.Experimental
MianserinThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium Sulfate.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Magnesium Sulfate.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
MidazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Milnacipran.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Magnesium Sulfate.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Investigational
MirtazapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumMagnesium Sulfate may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Magnesium Sulfate.Vet Approved
MorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Sulfate.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Magnesium Sulfate.Experimental
NabiloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NafcillinThe metabolism of Magnesium Sulfate can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium Sulfate.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Magnesium Sulfate.Investigational
NalbuphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Magnesium Sulfate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Nefazodone.Approved, Withdrawn
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
NeosaxitoxinMagnesium Sulfate may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Sulfate.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium Sulfate.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Magnesium Sulfate.Experimental
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium Sulfate.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Magnesium Sulfate.Investigational
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium Sulfate.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium Sulfate.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium Sulfate.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium Sulfate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium Sulfate.Approved
NitrazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate.Approved, Investigational
NitroprussideMagnesium Sulfate may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Magnesium Sulfate.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
NorfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Investigational
NormethadoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Magnesium Sulfate.Approved, Vet Approved
OlanzapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OleandomycinThe metabolism of Magnesium Sulfate can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Magnesium Sulfate.Experimental
OndansetronMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrlistatThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Magnesium Sulfate.Experimental, Investigational
OxazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxethazaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxethazaine.Approved, Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Magnesium Sulfate.Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Magnesium Sulfate.Experimental
OxprenololMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Magnesium Sulfate.Investigational
PaliperidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Sulfate.Approved
PancuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Paroxetine.Approved, Investigational
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
PenfluridolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Magnesium Sulfate.Approved
PentazocineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
PerazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium Sulfate.Approved, Investigational
PerospironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhenibutMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PhenobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoperidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxyethanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Magnesium Sulfate.Approved, Vet Approved
PimozideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium Sulfate.Approved
PipamperoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipecuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Magnesium Sulfate.Experimental
PipotiazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PiritramideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Magnesium Sulfate.Experimental
PitavastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Pitavastatin.Approved
PizotifenMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
PramipexoleMagnesium Sulfate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PravastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Pravastatin.Approved
PrazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Magnesium Sulfate.Approved
PregabalinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium Sulfate.Withdrawn
PrilocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProchlorperazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropanididMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
ProparacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
PSD502Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PyrantelMagnesium Sulfate may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Magnesium Sulfate.Experimental
QuazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinisocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacloprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Magnesium Sulfate.Experimental
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium Sulfate.Approved
RamelteonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RapacuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
RifabutinThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifaximin.Approved, Investigational
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
RisperidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RocuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Rocuronium.Approved
RomifidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleMagnesium Sulfate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Rosuvastatin.Approved
RotigotineMagnesium Sulfate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Magnesium Sulfate.Approved
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Magnesium Sulfate.Experimental
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Magnesium Sulfate.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium Sulfate.Approved, Vet Approved
ScopolamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SepranoloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Magnesium Sulfate.Approved
SertindoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Sertraline.Approved
SevofluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Magnesium Sulfate.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Magnesium Sulfate.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Magnesium Sulfate.Approved, Investigational
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Magnesium Sulfate.Experimental, Investigational
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium Sulfate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
Sodium phosphateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium Sulfate.Approved
SolithromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Solithromycin.Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
StiripentolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SuccinylcholineMagnesium Sulfate may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Magnesium Sulfate.Approved
SulpirideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
SultoprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SuvorexantMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Investigational
TandospironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
TasimelteonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Magnesium Sulfate.Approved
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Magnesium Sulfate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Magnesium Sulfate.Approved
TelithromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Telithromycin.Approved
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Magnesium Sulfate.Withdrawn
TemazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TerazosinTerazosin may increase the hypotensive activities of Magnesium Sulfate.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Magnesium Sulfate.Approved
TerodilineThe risk or severity of adverse effects can be increased when Terodiline is combined with Magnesium Sulfate.Experimental
TetrabenazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Investigational
TetrodotoxinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Magnesium Sulfate.Approved
TiagabineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TiletamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Magnesium Sulfate.Approved
TizanidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Magnesium Sulfate.Experimental
TolevamerThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Tolevamer.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Magnesium Sulfate.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Magnesium Sulfate.Approved, Vet Approved
TopiramateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TramadolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium Sulfate.Approved, Investigational
Trans-2-PhenylcyclopropylamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TriazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
Tricaine methanesulfonateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichloroethyleneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Approved
TriethylenetetramineThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Triethylenetetramine.Approved
TrifluoperazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TrifluperidolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Magnesium Sulfate.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Magnesium Sulfate.Approved, Investigational
TrimipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational, Withdrawn
TubocurarineMagnesium Sulfate may increase the neuromuscular blocking activities of Tubocurarine.Approved
TylosinThe metabolism of Magnesium Sulfate can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Magnesium Sulfate.Investigational
Valproic AcidMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VecuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Venlafaxine.Approved
VeraliprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Sulfate.Approved
VigabatrinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium Sulfate.Investigational
Vinyl etherMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Magnesium Sulfate.Approved, Investigational
VortioxetineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XenonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XylazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Sulfate.Approved
ZaleplonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Zimelidine.Withdrawn
ZiprasidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium Sulfate.Approved
ZolpidemMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational
ZuclopenthixolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Shinichi Yamamoto, Akifumi Sekitani, "BASIC MAGNESIUM SULFATE GRANULE, AND PROCESS FOR PRODUCTION THEREOF." U.S. Patent US20110042297, issued February 24, 2011.

US20110042297
General References
  1. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44. [PubMed:16002955]
  2. Yokoyama K, Takahashi N, Yada Y, Koike Y, Kawamata R, Uehara R, Kono Y, Honma Y, Momoi MY: Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010 Mar;86(3):187-91. doi: 10.1016/j.earlhumdev.2010.02.007. Epub 2010 Mar 12. [PubMed:20226604]
  3. Wedig KE, Kogan J, Schorry EK, Whitsett JA: Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006 Jun;26(6):371-4. [PubMed:16724078]
  4. Nassar AH, Sakhel K, Maarouf H, Naassan GR, Usta IM: Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis. Acta Obstet Gynecol Scand. 2006;85(9):1099-103. [PubMed:16929415]
  5. Malaeb SN, Rassi AI, Haddad MC, Seoud MA, Yunis KA: Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labour. Pediatr Radiol. 2004 May;34(5):384-6. Epub 2004 Feb 18. [PubMed:14985884]
  6. Matsuda Y, Maeda Y, Ito M, Sakamoto H, Masaoka N, Takada M, Sato K: Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8. [PubMed:9286718]
  7. Schanler RJ, Smith LG Jr, Burns PA: Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41. [PubMed:9194621]
  8. Santi MD, Henry GW, Douglas GL: Magnesium sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994 Mar-Apr;14(2):249-53. [PubMed:8188843]
  9. Holcomb WL Jr, Shackelford GD, Petrie RH: Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991 Oct;78(4):611-4. [PubMed:1923163]
  10. Cumming WA, Thomas VJ: Hypermagnesemia: a cause of abnormal metaphyses in the neonate. AJR Am J Roentgenol. 1989 May;152(5):1071-2. [PubMed:2705341]
  11. Lamm CI, Norton KI, Murphy RJ, Wilkins IA, Rabinowitz JG: Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr. 1988 Dec;113(6):1078-82. [PubMed:3193315]
  12. McGuinness GA, Weinstein MM, Cruikshank DP, Pitkin RM: Effects of magnesium sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980 Nov;56(5):595-600. [PubMed:7432730]
  13. Riaz M, Porat R, Brodsky NL, Hurt H: The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998 Nov-Dec;18(6 Pt 1):449-54. [PubMed:9848759]
External Links
Human Metabolome Database
HMDB14791
KEGG Drug
D01108
PubChem Compound
24083
PubChem Substance
46508411
ChemSpider
22515
ChEBI
32599
ChEMBL
CHEMBL2021423
Therapeutic Targets Database
DAP000201
PharmGKB
PA450302
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Magnesium_Sulfate
ATC Codes
V04CC02 — Magnesium sulfateA06AD04 — Magnesium sulfateA12CC02 — Magnesium sulfateB05XA05 — Magnesium sulfateD11AX05 — Magnesium sulfate
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives
  • 28:12.92 — Miscellaneous Anticonvulsants
  • 40:12.00 — Replacement Preparations
MSDS
Download (72.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticPremature Births1
1CompletedPreventionPaclitaxel-induced Neuropathy1
1CompletedSupportive CareHead and Neck Carcinoma1
1RecruitingTreatmentStroke, Ischemic1
1, 2CompletedPreventionPost Operative Pain1
1, 2CompletedTreatmentStroke, Acute1
1, 2CompletedTreatmentProphylaxis of preeclampsia1
1, 2RecruitingNot AvailableLack of Drug Action1
1, 2RecruitingTreatmentEpstein-Barr Virus (EBV) Infection and Neoplasia / X-linked Immunodeficiency With Magnesium Defect1
2Active Not RecruitingTreatmentMuscle Relaxation1
2CompletedPreventionAnalgesia1
2CompletedSupportive CareIdiopathic Scoliosis1
2CompletedTreatmentBronchiolitis / Magnesium, Abnormal Blood Level1
2CompletedTreatmentHand, Foot, and Mouth Disease1
2CompletedTreatmentNeuromuscular Block1
2RecruitingDiagnosticPain1
2RecruitingTreatmentPain, Neuropathic1
2TerminatedTreatmentTraumatic Brain Injury (TBI)1
2, 3Active Not RecruitingTreatmentPostoperative pain1
2, 3CompletedPreventionCerebral Palsy (CP) / Premature Labour1
2, 3CompletedPreventionCesarean Section; Shivering1
2, 3CompletedTreatmentPerinatal Anoxic-ischemic Brain Injury1
2, 3CompletedTreatmentPost Partum Severe Preeclampsia / Severe Pre-eclampsia Postpartum1
2, 3CompletedTreatmentSevere Pre-eclampsia With Postnatal Complication1
2, 3CompletedTreatmentSickle Cell Disorders1
2, 3RecruitingPreventionPostoperative pain1
2, 3WithdrawnPreventionChronic Hypertension / Gestational Hypertension / Preeclampsia / Pregnancy associated hypertension / Superimposed Preeclampsia1
2, 3WithdrawnTreatmentAsthma Bronchial1
2, 3WithdrawnTreatmentHeadaches1
3Active Not RecruitingPreventionNeoplasms, Brain / Seizures (Incl Subtypes)1
3CompletedPreventionCerebral Palsy (CP) / Intraventricular Hemorrhage / Periventricular Leukomalacia / Premature separation of placenta / Pulmonary Edemas1
3CompletedPreventionIncreased Intra Ocular Pressure (IOP)1
3CompletedPreventionSubarachnoid Hemorrhage1
3CompletedPreventionProphylaxis of preeclampsia1
3CompletedSupportive CareChemotherapeutic Agent Toxicity / Colorectal Cancers / Neuropathy / Neurotoxicity1
3CompletedSupportive CareColorectal Cancers / Neurotoxicity1
3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
3CompletedTreatmentBrain Injury / Concussion, Brain / Craniocerebral Injuries1
3CompletedTreatmentCerebrovascular Accidents1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentPerinatal Asphyxia , Moderate to Severe HIE1
3CompletedTreatmentSickle Cell Disorders1
3Not Yet RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
3RecruitingPreventionCerebral Palsy (CP)1
3RecruitingTreatmentBronchial Asthma1
3RecruitingTreatmentCesarean Section1
3RecruitingTreatmentHealthy Volunteers1
3TerminatedPreventionTransient Neurologic Syndrome1
3TerminatedSupportive CareNeuropathy / Pain / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
3Unknown StatusPreventionBrain Injury / Cerebral Palsy (CP)1
3Unknown StatusPreventionModerate Hypoxic Ischemic Encephalopathy / Severe Hypoxic Ischemic Encephalopathy1
4CompletedNot AvailableNeuromuscular Block1
4CompletedPreventionCardiovascular Morbidity / Intubation Complications1
4CompletedPreventionHemorrhage1
4CompletedPreventionHyperalgesia1
4CompletedPreventionLiving Donor Liver Transplantation / Reperfusion Injury1
4CompletedPreventionNeoplasm, Gastric1
4CompletedPreventionPostoperative pain1
4CompletedSupportive CareLumbar Spine Disc Herniation1
4CompletedSupportive CarePreeclampsia1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Hypocalcemia / Infections, Cytomegalovirus1
4CompletedTreatmentAdjunct to general anesthesia therapy / Intravenous Anesthesia1
4CompletedTreatmentNeuromuscular Blockade2
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentPre-eclampsia Aggravated1
4CompletedTreatmentPreeclampsia1
4CompletedTreatmentSupratentorial Brain Tumor1
4Not Yet RecruitingDiagnosticPreeclampsia1
4Not Yet RecruitingSupportive CareArthritis Knee / Dexmedetomidine / Magnesium Sulfate1
4Not Yet RecruitingTreatmentPreeclampsia Severe1
4RecruitingPreventionArrythmias1
4RecruitingPreventionPreterm Labor Without Delivery1
4RecruitingPreventionPsychomotor Agitation1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentDeep Neuromuscular Blockade / Magnesium Sulfate / Neuromuscular Blockade / Rocuronium1
4RecruitingTreatmentKnee Replacement Surgery1
4RecruitingTreatmentNeuromuscular Blockade1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentSevere Preeclampsia1
4SuspendedTreatmentPulmonary Disease, Chronic Obstructive1
4TerminatedPreventionPreeclampsia1
4TerminatedPreventionPremature Labour1
4TerminatedTreatmentMagnesium Sulphate / Pain / Post Pulmonary Resection1
4Unknown StatusNot AvailableEmergence Agitation in Children / Emergence Delirium / Postopertive Delirium1
4Unknown StatusPreventionAcute Agitation / Pediatric Disorder1
Not AvailableActive Not RecruitingOtherPregnancy associated hypertension / Prophylaxis of preeclampsia1
Not AvailableActive Not RecruitingTreatmentPremature separation of placenta1
Not AvailableCompletedNot AvailableAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailableCancer, Breast1
Not AvailableCompletedNot AvailableEasy of Laryngoscopy Manipulation / Heart Rate / Mean Arterial Pressure / Patient Reaction to Intubation and Cuff Inflation / Vocal Cord Position or Movement1
Not AvailableCompletedNot AvailableIntubating Conditions1
Not AvailableCompletedNot AvailableMagnesium Sulfate Pharmacokinetics and Pharmacodynamics1
Not AvailableCompletedNot AvailablePreeclampsia / Pregnancy1
Not AvailableCompletedNot AvailableSevere Sepsis / Shock, Septic1
Not AvailableCompletedOtherBreast Surgery1
Not AvailableCompletedOtherPain / Postoperative pain1
Not AvailableCompletedPreventionBenign muscle neoplasm1
Not AvailableCompletedPreventionColorectal Cancers1
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation1
Not AvailableCompletedPreventionNonvalvular Atrial Fibrillation / Pain, Neuropathic1
Not AvailableCompletedPreventionOpioid Use, Unspecified, Uncomplicated / Pain1
Not AvailableCompletedPreventionPost Operative Sore Throat1
Not AvailableCompletedPreventionProphylaxis of preeclampsia1
Not AvailableCompletedTreatmentAlagille Syndrome / Biliary Atresia / Cholestasis1
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableCompletedTreatmentIntubation Conditions / Observation of Neuromuscular Block / Surgical Conditions1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentObstetric Labour, Premature1
Not AvailableCompletedTreatmentWheezy Bronchitis1
Not AvailableNot Yet RecruitingPreventionProstatic Neoplasms1
Not AvailableNot Yet RecruitingTreatmentAsthma Acute / Asthma in Children1
Not AvailableNot Yet RecruitingTreatmentNeoplasms, Thyroid1
Not AvailableRecruitingNot AvailableNeuromuscular Blockade1
Not AvailableRecruitingNot AvailablePostpartum Depression1
Not AvailableRecruitingPreventionEmergence Delirium1
Not AvailableRecruitingPreventionPain1
Not AvailableRecruitingSupportive CarePostoperative pain1
Not AvailableRecruitingTreatmentIschemia, Brain / Strokes1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableRecruitingTreatmentPostpartum Hemorrhage1
Not AvailableRecruitingTreatmentPremature Labour1
Not AvailableRecruitingTreatmentRadius Fractures1
Not AvailableTerminatedTreatmentPremature Births / Premature Labour1
Not AvailableTerminatedTreatmentPreterm Premature Rupture of Membranes1
Not AvailableTerminatedTreatmentPrimary Hypomagnesemia (Disorder)1
Not AvailableUnknown StatusNot AvailableCerebral Aneurysms1
Not AvailableUnknown StatusNot AvailableHallux Valgus1
Not AvailableUnknown StatusPreventionPain2
Not AvailableUnknown StatusPreventionPostoperative pain1
Not AvailableUnknown StatusTreatmentAcute Severe Asthma1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentMuscle Relaxation1

Pharmacoeconomics

Manufacturers
  • Abraxis pharmaceutical products
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
SolutionIntramuscular; Intravenous500 mg
TabletOral
Powder, for solutionOral
Capsule, liquid filledOral
CapsuleOral
LiquidOral
CrystalOral; Topical1 g/g
GranuleOral1 g/g
GranuleOral100 kg/100kg
GranuleOral; Topical1 g/g
Granule, for solutionOral; Topical1 g/g
Granule, for solutionOral; Topical100 g/100g
Powder, for solutionOral100 %
GranuleTopical2.72 kg/2.72kg
PowderOral
PowderOral100 %
GranuleOral100 g/100g
Granule, for solutionOral1 g/g
Powder, for solutionOral1000 mg/g
InjectionIntravenous1 g/100mL
Injection, solutionIntramuscular; Intravenous.5 g/mL
Injection, solutionIntramuscular; Intravenous500 mg/mL
Injection, solutionIntravenous20 g/500mL
Injection, solutionIntravenous20 g/250mL
Injection, solutionIntravenous4 g/50mL
Injection, solutionIntravenous4 g/100mL
Injection, solutionIntravenous40 mg/mL
Injection, solutionIntravenous80 mg/mL
LiquidTopical45 %
Injection, solutionIntravenous1 g/100mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous20 mg/mL
LiquidIntramuscular; Intravenous200 mg
LiquidIntramuscular500 mg
LiquidIntramuscular; Intravenous500 mg
Granule, for solutionOral; Topical1 kg/kg
LiquidIntravenous
PowderTopical10 g/10g
CrystalOral; Topical100 g/100g
GranuleOral3.63 kg/3.63kg
Granule, for solutionOral1 kg/kg
KitOral
IrrigantIrrigation
LiquidIrrigation
SolutionIntravenous
Prices
Unit descriptionCostUnit
Elliotts b solution ampule4.71USD ml
Magnesium Sulfate 50% Solution 2ml Vial0.92USD vial
Magnesium sulfate powder0.29USD g
Magnesium-ns 6 g/50 ml bag0.29USD ml
Magnesium-ns 4 g/50 ml bag0.27USD ml
Magnesium-ns 3 g/50 ml bag0.26USD ml
Magnesium sulfate-ns 2 gm bag0.25USD ml
Magnesium sulfate-ns 1 gm bag0.24USD ml
Magnesium-d5w 1 gm/100 ml soln0.07USD ml
Magnesium-lr 20 g/500 ml0.03USD ml
Magnesium-lr 40 g/500 ml bag0.03USD ml
Magnesium-lr 50 g/500 ml bag0.02USD ml
Epsom salt 100% powder0.01USD g
Magnesium sulf 4% iv soln0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6946149No2003-03-072023-03-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)1124 °C (decomposition)Not Available
water solubility710 mg/mLNot Available
logP-0.91Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7487
Blood Brain Barrier+0.9646
Caco-2 permeable-0.6267
P-glycoprotein substrateNon-substrate0.9137
P-glycoprotein inhibitor INon-inhibitor0.9194
P-glycoprotein inhibitor IINon-inhibitor0.9904
Renal organic cation transporterNon-inhibitor0.9521
CYP450 2C9 substrateNon-substrate0.8775
CYP450 2D6 substrateNon-substrate0.8213
CYP450 3A4 substrateNon-substrate0.7007
CYP450 1A2 substrateNon-inhibitor0.7767
CYP450 2C9 inhibitorNon-inhibitor0.7602
CYP450 2D6 inhibitorNon-inhibitor0.9115
CYP450 2C19 inhibitorNon-inhibitor0.7547
CYP450 3A4 inhibitorNon-inhibitor0.9759
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9577
Ames testNon AMES toxic0.5773
CarcinogenicityCarcinogens 0.8111
BiodegradationReady biodegradable0.943
Rat acute toxicity2.4160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7988
hERG inhibition (predictor II)Non-inhibitor0.9446
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal sulfates
Direct Parent
Alkaline earth metal sulfates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Alkaline earth metal sulfate / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
magnesium salt, metal sulfate (CHEBI:32599)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18